Hepatic safety of sintilimab versus pembrolizumab in advanced non-small cell lung cancer: a retrospective observational cohort study - Scorecard - MDSpire
Advertisement
Hepatic safety of sintilimab versus pembrolizumab in advanced non-small cell lung cancer: a retrospective observational cohort study
Clinical Scorecard: Comparative Analysis of Hepatic Safety Between Sintilimab and Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Observational Study
At a Glance
Category
Detail
Condition
Advanced Non-Small Cell Lung Cancer (NSCLC)
Key Mechanisms
Comparison of hepatotoxicity profiles between Sintilimab and Pembrolizumab, both PD-1 inhibitors.
Target Population
Patients with advanced NSCLC treated with either Sintilimab or Pembrolizumab.
Care Setting
Retrospective observational study conducted in a clinical hospital setting.
Key Highlights
0
1
2
3
Guideline-Based Recommendations
Diagnosis
Monitor liver function indicators regularly in patients receiving PD-1 inhibitors.
Management
Consider both Sintilimab and Pembrolizumab as options for advanced NSCLC without increased hepatic risk.
Monitoring & Follow-up
Implement routine surveillance for hepatotoxicity in patients treated with PD-1 inhibitors.
Risks
Be aware of the potential for immune-related adverse events, including hepatotoxicity.
Patient & Prescribing Data
Chinese patients with advanced NSCLC treated with PD-1 inhibitors.
Both Sintilimab and Pembrolizumab show similar safety profiles regarding liver function.
Clinical Best Practices
Utilize propensity score matching to balance treatment groups in observational studies.
Apply Benjamini-Hochberg correction for multiple comparisons in safety assessments.
Conduct further prospective studies with diverse patient populations to validate findings.
